openPR Logo
Press release

Hereditary Angioedema - Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, and Treatment Outlook | Astria Therapeutics Inc, Attune Pharmaceuticals, BioMarin Pharmaceutical

02-22-2023 02:33 PM CET | Health & Medicine

Press release from: Global Insight Services

Hereditary Angioedema

Hereditary Angioedema

As per Global Insight services' assessment, about 7 prominent pharma and biotech giants are working on 7 drugs in the Lassa Fever - pipeline landscape globally. Lassa Fever Pipeline Insight, 2023" report by Global Insight Services provides a comprehensive analysis of the ongoing clinical development activities and growth prospect.

Download PDF Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.globalinsightservices.com/request-sample/GIS31264

Hereditary Angioedema is an infrequent inherited disease that causes substantial swelling in various body tissues, such as the abdomen or face caused by a low level or improper function of a protein called the C1 inhibitor. There are three types of hereditary angioedema namely type I, II, and III.

Hereditary Angioedema is mainly caused by a low level or improper function of a protein called C1 inhibitor.

Symptoms are severe abdominal pain and cramping, dehydration, diarrhea and shock, hoarse voice, difficulty swallowing, and difficulty breathing.

Hereditary Angioedema is diagnosed by blood tests that detect decreased levels of complement proteins and erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels.

Hereditary Angioedema is treated by medications, such as corticosteroids, antihistamines and epinephrine.

Read more about Hereditary Angioedema Insight here: https://www.globalinsightservices.com/reports/hereditary-angioedema-drug-pipeline-landscape/

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the treatment of Hereditary Angioedema treatment such as CSL312, Sebetralstat, BMN 331, PHVS719, and others. Key players involved in the development of therapies to treat Hereditary Angioedema are CSL Behring, Kalvista Pharmaceuticals and others. Four drugs are under late-stage Phase III clinical trials and three drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.

In Nov 2022, Ionis Pharmaceuticals Inc presented positive Phase II study of open label extension results of donidalosen. In Oct 2022, KalVista Pharmaceuticals announced positive Phase I data of sebetralstat. In August 2022, Global Biotechnology announed positive top-line Phase III results for garadacimab.

For In-Depth Competitive Analysis, Purchase this Report: https://www.globalinsightservices.com/checkout/single_user/GIS31264

Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like:

- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates

Contact Us:

Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hereditary Angioedema - Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, and Treatment Outlook | Astria Therapeutics Inc, Attune Pharmaceuticals, BioMarin Pharmaceutical here

News-ID: 2943961 • Views:

More Releases from Global Insight Services

Liver Disease Treatment Market: Expansion Fueled by Increasing Incidence of NAFLD, NASH, and Alcohol-Related Liver Disease | Overall Study Report
Liver Disease Treatment Market: Expansion Fueled by Increasing Incidence of NAFL …
The Liver Disease Treatment Market continues to expand rapidly as global awareness, early diagnosis, and advanced therapeutic approaches reshape patient care. With the market valued at $26.6 billion in 2024 and projected to reach $44.8 billion by 2034 at a steady 5.4% CAGR, demand for effective and accessible therapies is on the rise. The Liver Disease Treatment Market covers pharmaceuticals, biologics, vaccines, diagnostics, and liver transplant services designed to manage
Healthcare Supply Chain BPO Market: Expansion Fueled by Increasing Outsourcing of Procurement, Logistics, and Inventory Management | Overall Study Report
Healthcare Supply Chain BPO Market: Expansion Fueled by Increasing Outsourcing o …
The Healthcare Supply Chain BPO Market is rapidly evolving as healthcare providers worldwide seek smarter, leaner, and more resilient operations. With growing pressure to reduce costs, boost efficiency, and maintain uninterrupted patient care, outsourcing supply chain tasks has become a strategic necessity. The global Healthcare Supply Chain BPO Market is projected to grow from $3.05 billion in 2024 to $4.83 billion by 2034, reflecting a CAGR of 4.7%. This expansion
Robotics Crawler Camera System Market Rise by 2034 | Key Players: Inuktun Services, Deep Trekker, Envirosight
Robotics Crawler Camera System Market Rise by 2034 | Key Players: Inuktun Servic …
Market Overview Robotics Crawler Camera System Market is witnessing a major transformation as industries shift toward advanced inspection technologies that improve safety, accuracy, and operational efficiency. These robotic crawlers, equipped with high-resolution cameras and strong maneuverability, enable real-time inspection across pipelines, sewers, industrial tanks, and hazardous environments where manual inspections pose risks. As automation becomes central to industrial maintenance, the Robotics Crawler Camera System Market continues to gain momentum, supported by
Pet DNA Testing Market Growth to 2034 | Key Players: Wisdom Panel, Embark Veterinary, DNA My Dog
Pet DNA Testing Market Growth to 2034 | Key Players: Wisdom Panel, Embark Veteri …
Market Overview Pet DNA Testing Market is rapidly transforming the way pet owners understand the health, ancestry, and traits of their companion animals. As pets increasingly become family members, owners are demanding deeper insights into their pets' genetic makeup. The Pet DNA Testing Market offers services such as breed identification, disease risk assessments, trait analysis, and ancestry mapping. With advancements in genomics and the expansion of direct-to-consumer testing kits, the Pet

All 5 Releases


More Releases for Hereditary

Unraveling Hereditary Cancer With The Rising Demand For Hereditary Cancer Testin …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Will the Hereditary Cancer Testing Industry Market Size Be by 2025? The market encompassing hereditary cancer testing has exhibited robust expansion throughout the recent past, projecting an increase from its value of $4.32 billion in 2024 to reach $4.75 billion for the subsequent year, reflecting a consistent annual
Leber Hereditary Optic Neuropathy Treatment Market
Introduction Leber Hereditary Optic Neuropathy (LHON) is a genetic condition that leads to severe vision loss, primarily affecting young adults. This disorder is caused by mutations in mitochondrial DNA, which impairs the function of retinal ganglion cells. As awareness of LHON has grown, so too has the focus on its treatment options. The LHON treatment market is evolving rapidly, driven by advancements in genetic therapies, pharmaceuticals, and supportive care strategies. This
Hereditary Hemochromatosis Market - Redefining Care, Inspiring Hope: Hereditary …
Newark, New Castle, USA: The "Hereditary Hemochromatosis Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. Hereditary Hemochromatosis Market: https://www.growthplusreports.com/report/hereditary-hemochromatosis-market/8793 This latest report researches the industry structure, sales, revenue,
Hereditary Angioedema Market Research Report 2032
DelveInsight's "Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the Hereditary Angioedema, historical and forecasted epidemiology as well as the Hereditary Angioedema market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Hereditary Angioedema (HAE) is a rare genetic disorder caused by the deficiency in functional C1 inhibitor (C1INH) that results in recurrent attacks of localized subcutaneous or
Hereditary Angioedema - Drug Pipeline Landscape, 2022
Global Hereditary Angioedema Market report from Global Insight Services is the single authoritative source of intelligence on hereditary angioedema market. The report will provide you with analysis of impact of latest market disruptions such as Russia-Ukraine war and Covid-19 on the market. Report provides qualitative analysis of the market using various frameworks such as Porters' and PESTLE analysis. Report includes in-depth segmentation and market size data by categories, product types,
Hereditary Angioedema - Drug Pipeline Landscape, 2022
Hereditary Angioedema is an infrequent inherited disease that causes substantial swelling in various body tissues, such as the abdomen or face caused by a low level or improper function of a protein called the C1 inhibitor. There are three types of hereditary angioedema namely type I, II, and III. Hereditary Angioedema is mainly caused by a low level or improper function of a protein called the C1 inhibitor. Read more about Hereditary